Botulinum Toxin Potency Verification via Albumin Proxy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Measuring the exact content of bioactive agents like Botox®, which contains minute quantities of botulinum toxin, is complex and difficult in clinical settings due to its high toxicity and varying solution concentrations, necessitating a simple and accurate method for potency verification.
Innovation Solution
A method involving the use of a marker compound, such as human serum albumin or sodium chloride, to determine the concentration of botulinum toxin in a formulation by establishing a correlation and using detectable and quantifiable physical means like spectroscopy or chromatography to measure the bioactive agent's content.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If direct measurement of botulinum toxin is performed, then measurement precision is improved, but device complexity and cost increase significantly
Solution Approach 1:
The patent uses an intermediary substance (bromocresol green dye) that binds to albumin in the formulation. Instead of directly measuring the botulinum toxin, the method measures the dye-albumin complex formation, which correlates to the toxin concentration. This intermediary approach simplifies the measurement while maintaining accuracy.
Solution Approach 2:
The patent creates a measurable proxy or copy of the toxin concentration by measuring albumin content through dye binding. Rather than detecting the toxin directly, it measures a correlated parameter (albumin-dye complex) that serves as a reliable indicator of toxin concentration, making the measurement simpler and less expensive.
2Measurement precision
If direct measurement of botulinum toxin is performed, then measurement precision is improved, but cost increases significantly
Solution Approach 1:
The patent employs inexpensive reagents (bromocresol green dye and albumin) that can be used in simple, disposable test configurations. This replaces expensive, complex direct toxin measurement systems with affordable chemical reagents and basic spectrophotometric equipment, dramatically reducing measurement costs.
Solution Approach 2:
By measuring a proxy parameter (albumin concentration via dye binding) rather than the toxin itself, the patent creates a cost-effective measurement system. The proxy measurement achieves sufficient precision for clinical verification without requiring expensive specialized equipment or reagents.
3Adaptability or versatility
If varying volumes of saline or water are used to dissolve Botox powder, then adaptability is improved, but measurement precision deteriorates due to varying concentrations
Solution Approach 1:
The patent incorporates a feedback mechanism where the measured albumin concentration is used to calculate the actual toxin units delivered. The system adjusts for varying dilution volumes by measuring the albumin-dye complex and using the known albumin-toxin ratio to back-calculate the precise toxin concentration, regardless of the initial dissolution volume.
Solution Approach 2:
The patent changes the measurement parameter from direct toxin concentration to albumin concentration. Since albumin is present in fixed amounts in the formulation regardless of dilution volume, measuring albumin provides a stable reference point that can be used to calculate toxin concentration even when dissolution volumes vary.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method allows for simple and accurate measurement of bioactive agents, enabling independent verification of potency and ensuring appropriate dosing, reducing the complexity and cost associated with direct toxin measurement.
Implementation Method 1
determination of a botulinum toxin (e.g., Clostridium Botulinum A) in a liquid formulation... determining the concentration of the marker compound in the formulation... determining the concentration of the Clostridium Botulinum A using the concentration of the marker compound
Data Source
AI summary
A method of measuring the concentration of a bioactive agent is disclosed.